Sign In
1 Mar 2021 07:00
e-therapeutics plc
("e-therapeutics" or the "Company")
Board Changes
Oxford, UK, 1 March 2021 - e-therapeutics plc (AIM: ETX) today announces the following changes to its Board of Directors. With immediate effect, the role of Executive Chairman and Chief Executive will be split so that Professor Trevor Jones, an Independent Non-Executive Director of the Company since 2015, will assume the role of Independent Non-Executive Chairman and Ali Mortazavi will continue in his role as Chief Executive Officer.
Trevor has over 40 years' experience in the pharmaceutical and biotechnology industries as well as in academia. He has held significant roles including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal and Malarone. He is Visiting Professor at King's College, London and holds honorary degrees and Gold Medals from seven universities.
The Company continues to search for an additional Non-Executive Director to further strengthen the Board.
Professor Trevor Jones, Non-Executive Chairman of e-therapeutics, commented: "I am delighted with my appointment. e-therapeutics has a world-class team of scientists who are discovering entirely novel therapeutics using their unique approach to network pharmacology. The appointment last year of Ali Mortazavi has led to a step-change in the Company's performance and we are in a strong position to continue our successful internal programmes and partnerships with major pharmaceutical and biotech companies."
Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented: "I am very pleased that Trevor has agreed to become the Non-Executive Chairman of e-therapeutics. Having served as a Non-Executive Director for many years, Trevor has an in-depth knowledge of the Company and I am very much looking forward to working more closely with him.
"Trevor has had a distinguished career at the helm of leading pharmaceutical and governmental organisations during which he has made major contributions to human health and to business. His breadth of experience in all aspects of the biopharma industry will be invaluable to us as we strive to achieve our long-term ambitions in drug development."
Enquiries:
e-therapeutics plc |
|
Ali Mortazavi, CEO | Tel: +44 (0)1993 883 125 |
| www.etherapeutics.co.uk |
|
|
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker |
|
Matthew Johnson/Caroline Rowe (Corporate Finance) |
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
|
|
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
Follow the stocks
